Johnson & Johnson Innovation – JJDC

Rowan Chapman is co-founder at BEVC and serves as an entrepreneur, investor, and board member. With experience spanning startups to Fortune 50 companies, Chapman has executed numerous transactions in therapeutics, digital health, research tools, diagnostics, vaccines, and medical devices, and maintains expertise in team building, business planning, equity investing, M&A, and LP relations. Chapman holds NACD Directorship Certification.

Asha Nayak is a physician and venture capitalist who serves as Global Head and Corporate Vice President of Consumer Health Investments at Johnson & Johnson Innovation, where she has grown the venture portfolio to 22 companies and facilitated multiple partnerships and acquisitions. She has held senior positions at Intel and Medtronic in product development and authored over 20 issued patents in cardiac devices, drug-delivery systems, and genomic analytics platforms. Nayak maintains an active medical practice and has served on 17 corporate boards overseeing companies developing innovations in cardiology, psychiatry, allergy prevention, addiction treatment, and personalized medicine.

Chris Picariello is President of Johnson & Johnson Innovation - JJDC, Inc. He holds a Bachelor of Science degree in Accounting from LaSalle University and began his career at Johnson & Johnson through the Finance Leadership Development Program, advancing through various finance roles across multiple sectors within the company.

Elizabeth Wu is a Senior Director of External Scientific Innovation Transactions at Johnson & Johnson Innovative Medicine. She has over ten years of experience in healthcare and consumer health, working on partnerships and investments in early-stage biopharma companies to support the development of innovative technologies and business models.

Jonathan Yaari is a co-founder and Chief Product Officer at Sollapay with over 10 years of experience as a founder and product leader in B2B SaaS, fintech, and e-commerce. He has founded three companies, one of which he successfully sold, and has built and scaled AI products across machine learning, deep learning, and large language models since 2016. Yaari has led product vision, design, and development at fast-growing startups and mentors founding teams at Techstars and IDC School of Entrepreneurship.

Noam Krantz is Senior Vice President at Guardant Health, where he works on cancer care innovation. He serves as an investor, company advisor, board member, and corporate development leader with expertise in mergers and acquisitions, corporate finance, and strategy.

Paul Stoffels served as Chief Scientific Officer at Johnson & Johnson, where he oversaw global R&D and the launch of 25 innovative medicines, including 10 in oncology. He co-founded Galapagos NV, serving as CEO and Chair before transitioning to an advisory role focused on cell therapy development and manufacturing platforms. Stoffels holds medical degrees from the University of Diepenbeek and University of Antwerp, with additional training in infectious diseases and tropical medicine, and began his career as a physician conducting HIV and tropical disease research in Africa.

Renee Compton Ryan is co-founder and CEO of PinPrint, a patient-centric microarray drug delivery and tissue sampling company. She previously served as CEO of Cala Health, a bioelectronic medicine company focused on wearable therapies for chronic diseases, and brings over 25 years of experience in healthcare investing and leadership. She currently serves as a board member at Cubby Beds and has participated in M&A transactions, venture capital investments, and strategic partnerships throughout her career.

Sanjay Mistry is Vice President of Venture Investments and New Company Creation at Johnson & Johnson Innovation – JJDC Inc., where he leads the identification and funding of early-stage healthcare companies. He serves as Director on the Board of Agni Bio and has held board positions at TRex Bio and Abdera Therapeutics, as well as prior board roles at companies including Manifest Technologies, Rapport Therapeutics, RainDance Technologies, and Rapid Micro Biosystems. His background includes involvement in the formation of multiple biotech companies, including Provention Bio, Fusion Pharmaceuticals, and Aro Therapeutics, and he holds training in clinical pharmacology with 20 peer-reviewed publications and over 200 issued patents.

Member of the Investment Advisory Committee; Regional Head at Johnson & Johnson Innovation, West North America.

Tamir Meiri is a Principal for Venture Investments at Johnson & Johnson Innovation - JJDC, Inc., where he leads the investment process in Israel and Europe across medical devices, digital technologies, and consumer products. He holds a B.Sc. in Chemistry from Tel Aviv University and an MBA in Finance from the Interdisciplinary Center in Herzliya, with background in biomedical engineering and entrepreneurship.

V. Kadir Kadhiresan is Vice President of Venture Investments at Johnson and Johnson Development Corporation. He brings over 25 years of senior leadership experience in healthcare, with background spanning venture capital, corporate business development, strategic planning, mergers and acquisitions, and global product development.